Cite
HARVARD Citation
Jeong, H. et al. (2021). Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer. International journal of cancer. 149 (4), pp. 917-924. [Online].